We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

170 hedge funds and large institutions have $3.23B invested in Blueprint Medicines in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 39 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 12

236% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $5.63M

85% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 39

28% more capital invested

Capital invested by funds: $2.53B → $3.23B (+$703M)

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

23% more funds holding

Funds holding: 138 → 170 (+32)

6.93% more ownership

Funds ownership: 92.75% → 99.69% (+6.9%)

Holders
170
Holders Change
+32
Holders Change %
+23.19%
% of All Funds
3.86%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.23%
New
44
Increased
72
Reduced
39
Closed
12
Calls
$18.9M
Puts
$5.63M
Net Calls
+$13.3M
Net Calls Change
+$12.4M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$97.3M
2
HIM
Hillhouse Investment Management
Cayman Islands
+$54.1M
3
PA
Perceptive Advisors
New York
+$50.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$39.7M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.6M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$53.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$52M
3
CCM
Cadian Capital Management
New York
-$21.9M
4
BI
BVF Inc
California
-$16.9M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$14.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
51
Ameriprise
Minnesota
$5.26M +$1.09M +15,499 +29%
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$5.06M +$342K +4,861 +8%
Swiss National Bank
53
Swiss National Bank
Switzerland
$4.88M +$950K +13,500 +26%
Invesco
54
Invesco
Georgia
$4.6M -$824K -11,716 -16%
TD Asset Management
55
TD Asset Management
Ontario, Canada
$4.58M +$648K +9,215 +18%
SIM
56
Spark Investment Management
New York
$4.2M +$732K +10,400 +23%
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$3.85M +$178K +2,527 +5%
CCI
58
Columbus Circle Investors
$3.79M +$3.54M +50,290 New
Two Sigma Investments
59
Two Sigma Investments
New York
$3.79M -$4.26M -60,483 -55%
CS
60
Candriam SCA
Luxembourg
$3.32M +$3.1M +44,000 New
Balyasny Asset Management
61
Balyasny Asset Management
Illinois
$3.28M -$3.29M -46,707 -52%
Allianz Asset Management
62
Allianz Asset Management
Germany
$3.27M +$2.54M +36,117 +500%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$3.08M -$290K -4,122 -9%
State of Wisconsin Investment Board
64
State of Wisconsin Investment Board
Wisconsin
$2.9M +$802K +11,400 +42%
NIP
65
Nicholas Investment Partners
California
$2.85M +$25.4K +361 +1%
GC
66
Guggenheim Capital
Illinois
$2.74M +$2.56M +36,346 New
CS
67
Credit Suisse
Switzerland
$2.68M -$753K -10,707 -23%
MCM
68
Moore Capital Management
New York
$2.64M +$2.46M +35,000 New
AQR Capital Management
69
AQR Capital Management
Connecticut
$2.57M -$1.19M -16,927 -33%
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.43M +$193K +2,748 +9%
Hudson Bay Capital Management
71
Hudson Bay Capital Management
Connecticut
$2.26M +$2.11M +30,000 New
AIG
72
American International Group
New York
$2.16M +$183K +2,608 +10%
KAM
73
Kazazian Asset Management
Florida
$2.16M +$275K +3,911 +16%
First Trust Advisors
74
First Trust Advisors
Illinois
$2.1M -$1.41M -20,046 -42%
ProShare Advisors
75
ProShare Advisors
Maryland
$2.07M +$192K +2,731 +11%
1 2
3
4 5

BPMC Hedge Fund Activity: Q4 2017 in Review

170 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2017, worth a combined $3.23B — up 28% from $2.53B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new BPMC positions and 12 closed out — a net gain of 32 holders — while 72 added to existing stakes and 39 trimmed.

The largest buyer was Vanguard Group, adding an estimated $97.3M. The largest seller was PFM Health Sciences, cutting an estimated $53.6M.

  • 170 institutional investors held Blueprint Medicines (BPMC) as of Q4 2017, up from 138 in Q3 2017.
  • Funds reported $3.23B of Blueprint Medicines stock for Q4 2017, up 28% quarter-over-quarter.
  • 44 funds opened new Blueprint Medicines positions in Q4 2017 and 12 closed out, a net change of +32 holders.
  • The largest Blueprint Medicines buyer in Q4 2017 was Vanguard Group, an estimated $97.3M added.
  • The largest Blueprint Medicines seller in Q4 2017 was PFM Health Sciences, an estimated $53.6M sold.

Based on aggregated 13F filings for Q4 2017.